Advertisement

Prostate Cancer Detection Using a Noninvasive Method for Quantifying miRNAs

  • Mauricio Rodríguez-DorantesEmail author
  • A. Ivan Salido-Guadarrama
  • Pilar García-Tobilla
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1165)

Abstract

Cancer is one of the diseases with more incidence in industrialized countries. Early detection is important for patient survival in terms of treatment and clinical decisions. Several methods have been described to improve detection, diagnostic, and treatment in cancer, but the diagnostic methods are very aggressive for patients. Biopsies have been the gold standard to determine the clinical pathological characteristics of cancer tissues for many years. The biopsies procedure is very uncomfortable for the patients, and in many cases the results are negative to cancer. Therefore, patients are submitted to a second round of biopsies, because their clinical conditions implicate the presence of neoplasia. During the last years, noninvasive methods have shown relevance because they could be good indicators for cancer detection at molecular level. Molecular signatures have been included to characterize different stages of the disease, and thereby the objective is to prevent unnecessary biopsies. Several body fluids as urine, serum, blood, semen, saliva, etc. have been used. In fluids, miRNA detection provides a promising tool to obtain molecular signatures for different types of cancer. Urine represents a very good option to find molecules representative of tumor status in prostate cancer. The presence or the absence of miRNA involved in the development of the disease has been demonstrated. In this chapter we describe a method to quantify mature miRNA signatures using a noninvasive test using a body fluid such as urine.

Key words

Body fluids miRNAs Microarrays Molecular signature Biopsies 

References

  1. 1.
  2. 2.
    Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E (eds) (2003) Cancer medicine, 6th edn. Hamilton, MA: BC DeckerGoogle Scholar
  3. 3.
    Hanahan D, Weinberg RA (2000) The Hallmarks of cancer. Cell 100:57–70PubMedCrossRefGoogle Scholar
  4. 4.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRefGoogle Scholar
  5. 5.
    GLOBOCAN (2008) Prostate cancer incidence, mortality and prevalence worldwide in 2008, GLOBOCAN Project. http://globocan.iarc.fr/.
  6. 6.
    Narain V, Cher ML, Wood DP Jr (2002) Prostate cancer diagnosis, staging and survival. Cancer Metastasis Rev 21:17–27PubMedCrossRefGoogle Scholar
  7. 7.
    Hansen LL (2006) Molecular diagnosis of breast cancer, in prevention and treatment of age-related diseases. Springer, The NetherlandsGoogle Scholar
  8. 8.
    Kohler C, Barekati Z, Radpour R et al (2011) Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer Res 31:2623–2628PubMedGoogle Scholar
  9. 9.
    Pathak AK, Bhutani M, Kumar S et al (2006) Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52:1833–1842PubMedGoogle Scholar
  10. 10.
    Wroclawski ML, Serpa-Neto A, Fonseca NL et al (2013) Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumour Biol 34:2921–2927PubMedCrossRefGoogle Scholar
  11. 11.
    Allegra A, Alonci A, Campo S et al (2012) Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer. Int J Oncol 41:1897–1912PubMedGoogle Scholar
  12. 12.
    Filella X, Foj L, Milá M et al (2013) PCA3 in the detection and management of early prostate cancer. Tumour Biol 34:1337–1347PubMedCrossRefGoogle Scholar
  13. 13.
    Roobol MJ, Haese A, Bjartell A (2011) Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 50(Suppl 1):85–89PubMedCrossRefGoogle Scholar
  14. 14.
    Weber JA, Baxter DH, Zhang S et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741PubMedCrossRefGoogle Scholar
  15. 15.
    Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9:102–114PubMedCrossRefGoogle Scholar
  16. 16.
    Rana TM (2007) Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8:23–36PubMedCrossRefGoogle Scholar
  17. 17.
    Brennecke J, Hipfner DR, Stark A et al (2003) Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113:25–36PubMedCrossRefGoogle Scholar
  18. 18.
    Bushati N, Cohen SM (2007) microRNA functions. Annu Rev Cell Dev Biol 23:175–205PubMedCrossRefGoogle Scholar
  19. 19.
    Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854PubMedCrossRefGoogle Scholar
  20. 20.
    Rajewsky N, Socci ND (2004) Computational identification of microRNA targets. Dev Biol 267:529–535PubMedCrossRefGoogle Scholar
  21. 21.
    Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524–15529PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Calin GA, Sevignani C, Dumitru CD et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101:2999–3004PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Ambs S, Prueitt RL, Yi M et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68:6162–6170PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Calin GA, Ferracin M, Cimmino A et al (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793–1801PubMedCrossRefGoogle Scholar
  25. 25.
    Calin GA, Liu CG, Sevignani C et al (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101:11755–11760PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Fassan M, Baffa R, Palazzo JP et al (2009) MicroRNA expression profiling of male breast cancer. Breast Cancer Res 11:R58PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Lorio MV, Visone R, Di Leva G et al (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67:8699–8707CrossRefGoogle Scholar
  28. 28.
    Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRefGoogle Scholar
  29. 29.
    Tong AW, Fulgham P, Jay C et al (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16:206–216PubMedGoogle Scholar
  30. 30.
    Volinia S, Calin GA, Liu CG et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103:2257–2261PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Kahlert C, Kalluri R (2013) Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med 91:431–437PubMedCrossRefGoogle Scholar
  32. 32.
    Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Mauricio Rodríguez-Dorantes
    • 1
    Email author
  • A. Ivan Salido-Guadarrama
    • 1
  • Pilar García-Tobilla
    • 1
  1. 1.Instituto Nacional de Medicina GenómicaMéxicoMéxico

Personalised recommendations